Latest news
Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - BenzingaBenzinga · Fri, 31 Jul 2026 14:09:17 GMTREPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - TradingViewTradingView · Fri, 31 Jul 2026 10:45:28 GMTCapricor CEO won’t rule out legal action against FDA after negative adcomm - BioSpaceBioSpace · Fri, 31 Jul 2026 07:00:00 GMTReplimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy - BioSpaceBioSpace · Thu, 30 Jul 2026 07:00:00 GMTReplimune melanoma drug wins support of FDA panel - BioPharma DiveBioPharma Dive · Thu, 30 Jul 2026 07:00:00 GMTPharmaTher Launches Personaliz3D Peptides Division Following Positive FDA Advisory Committee Recommendations - kalkine.cakalkine.ca · Mon, 27 Jul 2026 14:16:11 GMTPharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations - TMX NewsfileTMX Newsfile · Mon, 27 Jul 2026 07:00:00 GMT